Information for Investors

We believe providing an individualized risk of spontaneous premature birth and other pregnancy complications is a critical first step to improving maternal and newborn health. Our vision is to deliver pivotal and actionable information to pregnant women, their physicians and healthcare payers to significantly improve maternal and neonatal health and to meaningfully reduce healthcare costs. 

Corporate Presentation
Relevant Publications

Find the latest publications here.

Recent News
Oct 4, 2022

The value created by applying Sera's PreTRM® test and treat strategy enables savings to be shared in an innovative value-based paradigm SALT LAKE CITY, COPPELL, Texas and SAN MATEO, Calif., Oct....

Sep 22, 2022

First and only broadly clinically validated test to provide accurate and actionable information to help reduce the morbidity, mortality, and costs associated with preterm birth Salt Lake City and...

Aug 10, 2022

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients,...

View More

Upcoming Events

Email Alerts

Sign up for our investor relations email list here.